To include your compound in the COVID-19 Resource Center, submit it here.

Conatus' emricasan meets Phase II endpoint

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) jumped $1 (17%) to $6.76 on Thursday after it said

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE